BOEHRINGER-INGELHEIM
3.8.2022 12:07:11 CEST | Business Wire | Press release
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continued to increase its supply of medicine to patients in the first half of 2022, as it expanded its research pipeline in an increasingly challenging economic, political and regulatory environment.
Boehringer Ingelheim has experienced strong momentum through greater investment in Research & Development (R&D), accelerated development of its pipeline and business development opportunities. The company also closed 11 R&D partnership and license deals so far this year, with a focus on new modalities such as protein degraders, antimicrobial resistance, regenerative medicine, oncology and data science.
Fueled by ongoing strong demand for the company’s human heart failure, diabetes and respiratory treatments, and its products for pets, currency-adjusted net sales rose by 9.5 percent to 11.2 billion EUR.
“Despite a volatile economic environment, we were able to supply more patients with the treatments that make a difference to them, while advancing our pipeline in Human Pharma as well as in Animal Health striving to transform lives where medical need is high,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors.
Boehringer Ingelheim has earmarked 25 billion EUR for investments in R&D and an additional 7 billion EUR for new production technologies over the next five years. The company anticipates running eight active human medicines registrational trials by the end of the year, with the potential of bringing 15 new products to patients by 2027.
“Although we expect economic uncertainties to persist in the second half of the year, we remain confident that we can achieve our goals for 2022 and proceed on our innovation-driven path,” said Michael Schmelmer, Member of the Board of Managing Directors, responsible for Finance & Group Functions. “We will continue to focus on and invest in our most promising assets to bring the best value to patients.”
Net sales in Human Pharma were up 11.8 percent (currency-adjusted) during the first six months of 2022 at 8.4 billion EUR, mainly driven by diabetes treatment of the JARDIANCE® family at 2.5 billion EUR and the respiratory medicine OFEV® at 1.5 billion EUR.
Growth in the Animal Health business amounted to 1.2 percent (currency-adjusted) to 2.4 billion EUR. The business was impacted by challenging market conditions including inflation, COVID-19 lockdowns, outbreaks of African Swine Fever and supply chain constraints. Net sales of NEXGARD® , a parasiticide for dogs, increased 13.7 percent (currency-adjusted) to 593 million EUR, while HEARTGARD® , which prevents heartworm disease in dogs, rose 4.4 percent to 197 million EUR.
For the remainder of the year Boehringer Ingelheim is anticipating regulatory updates for Spesolimab, a potential treatment for flares in generalized pustular psoriasis (GPP), a rare, life-threatening neutrophilic skin disease. The company will also present promising data on JARDIANCE® for the treatment of patients with chronic kidney disease. In addition, major product launches are expected for Animal Health in 2022 and 2023.
Click here for the full release: https://www.boehringer-ingelheim.com/about-us/corporate-profile/boehringer-ingelheim-2022-half-year-results
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005402/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Joins Hong Kong Regulators’ GenA.I. Sandbox++ to Advance Bank Liquidity Management with AI27.8.2026 12:00:00 CEST | Press release
Ant Bank and Bettr aim to establish 24/7 liquidity risk management ecosystem Ant International’s Ant Bank, a digital bank based in Hong Kong, and Bettr, its inclusive embedded financial solutions provider, have been selected to participate in Hong Kong regulators’ GenA.I. Sandbox++, focusing on the liquidity risk management track. Ant Bank will leverage Ant International's Falcon Time-Series Transformer (TST) AI Model 2.0 to enhance its FX and liquidity management capabilities. The partnership will deploy granular, statistically-grounded daily forecasts, to support more precise and proactive liquidity planning for the bank's real-time treasury management — strengthening its capabilities to support a 24/7 financial ecosystem. As Hong Kong's only digital bank deeply integrated with an e-wallet, Ant Bank aims to leverage technology to provide innovative, inclusive and customer-centric digital financial services. To enhance customer experience, the bank sought to integrate AI and LLM techn
74% of Shoppers Use AI for Discovery—NIQ Showcases What That Means for the Consumer Purchase Journey in New Report27.8.2026 12:00:00 CEST | Press release
New NIQ & World Data Lab report reveals how AI, retail media, and social commerce are transforming the consumer purchase journey Consumers are increasingly turning to new technologies to help navigate a more complex shopping landscape. Nearly three-quarters of shoppers now use AI for product discovery, while retail media has grown into a $184 billion global market. Together, these shifts are reshaping how products are discovered, evaluated, and ultimately purchased. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827177247/en/ AI is becoming the new gatekeeper of product discovery. NIQ has released A Tale of Two Consumers: The Polarized Mindsets Reshaping Global Consumption, a new global report in collaboration with World Data Lab showing how artificial intelligence, retail media networks, and social commerce are transforming the path to purchase and influencing which products consumers ultimately buy. The findings build o
Ant International’s R2 Enters Brazil, Bringing Embedded Credit Technology to Serve SMBs and Gig Workers27.8.2026 11:00:00 CEST | Press release
R2 today announced its expansion into Brazil, marking the company's entry into Latin America's largest economy. With the support of Ant International, a leading global digital payment, digitisation and FinAI solutions provider, R2 will partner with digital platforms across Brazil to embed working capital solutions directly into the products their merchants and gig workers already use. For digital platforms, marketplaces, payment providers, ecommerce companies, and others serving SMBs and gig workers, R2 provides a proven embedded credit technology solution that enables them to offer financing to their users without building credit operations themselves, and without taking on credit risk. The result is a new revenue stream and a stronger value proposition for their merchant base. For the businesses and workers those platforms serve, it means access to working capital based on how they actually perform, not on documentation that most of them don't have. "Brazil is a defining milestone in
Samsung Display Elevates Gaming Immersion with QD-OLED at Gamescom 202627.8.2026 10:30:00 CEST | Press release
Collaborates with global game companies CAPCOM, KRAFTON and CD PROJEKT RED to showcase QD-OLED gaming experiences Offers hands-on gameplay of highly anticipated titles on about 180 QD-OLED products, highlighting QD-OLED’s fast response times, true blacks and rich color reproduction Begins mass production of 24.5-inch QD-OLED panels for eSports and first-person shooter (FPS) gaming by year-end Global PC manufacturers unveil plans to launch new products featuring Samsung Display’s 24.5-inch QD-OLED panels Samsung Display’s QD-OLED holds nearly 75% of the self-emissive monitor panel market, with lineup expansion set to further strengthen market leadership Samsung Display will showcase the gaming performance advantages of QD-OLED through collaborations with global game companies at gamescom 2026, the world’s largest gaming exhibition. The company also announced plans to begin mass production of 24.5-inch QD-OLED panels optimized for eSports and FPS games by the end of this year, underscori
SCP Standard Capital Partners AG: VANEA Defence Unveils ATOMZA®, the First Production-Ready Drone Defence System for Civilian Operators27.8.2026 08:49:00 CEST | Press release
ATOMZA® is the first counter-drone mitigation solution that can be deployed by civilian operators without sovereign enforcement powers.VANEA is opening up counter-UAS capabilities to airports, large-scale events, critical infrastructure and other sites exposed to security threats or espionage – a market previously restricted to public security authorities with the legal mandate to actively counter drones.ATOMZA is already undergoing operational testing with security authorities and critical infrastructure operators, with military trials to follow. Commercial availability for civilian operators starts immediately. VANEA Defence today unveiled ATOMZA, the world’s first drone defence system designed for civilian deployment that can be operated by private organisations without sovereign enforcement powers. The system opens up a previously inaccessible market for active counter-UAS solutions, which until now have largely been restricted to public security authorities legally authorised to i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom